Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LIG1 | P18858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 3/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042380 | 0.85 | ERN1 (0.57) | TSHRHPGDMAPK1HSD17B10ALDH1A1 | |
| SCHEMBL16135175 | 0.83 | ERN1 (0.44) | GAAHPGDALDH1A1KDM4EERN1 | |
| SCHEMBL5042464 | 0.79 | ALDH1A1 (0.49) | TSHRGAAHPGDALDH1A1KDM4E | |
| SCHEMBL3954852 | 0.78 | GAA (0.41) | TSHRGAAHPGDMAPK1HSD17B10 | |
| SCHEMBL29752542 | 0.76 | TSHR (0.45) | TSHRGAAHPGDMAPK1HSD17B10 | |
| SCHEMBL4780536 | 0.76 | HPGD (0.46) | TSHRGAAHPGDMAPK1HSD17B10 | |
| SCHEMBL28495118 | 0.76 | ERN1 (0.59) | TSHRGAAHPGDMAPK1HSD17B10 | |
| SCHEMBL2664412 | 0.75 | CA12 (0.47) | TSHRGAAHPGDMAPK1HSD17B10 | |
| SCHEMBL20136050 | 0.74 | TSHR (0.40) | TSHRGAAHPGDMAPK1HSD17B10 | |
| SCHEMBL28607462 | 0.74 | ALDH1A1 (0.43) | TSHRGAAHPGDMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | TSHR 4871/4885GAA 182/4885HPGD 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.